Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation-Reference-Cited by-同舟云学术

Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation

Published:2018-05-04 Issue: Volume: Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Feng Xu‑Qin¹,Rong Li‑Wen¹,Wang Rui‑Xue²,Zheng Xue‑Lian²,Zhang Lei²,Zhang Lin²,Lin Yong²,Wang Xia²,Li Zhi‑Ping¹

Affiliation:

1. Department of Abdomen Oncology, Cancer Center of West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China

2. Laboratory of Molecular and Translational Medicine, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University) of Ministry of Education, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Novel Combinatorial Regimen Using Sorafenib and Uttroside B, A US FDA-designated ‘Orphan Drug’, for the Treatment of Hepatocellular Carcinoma;Anti-Cancer Agents in Medicinal Chemistry;2024-08-09

2. HepG2 exosomes coated luteolin nanoparticles remodeling hepatic stellate cells and combination with sorafenib for the treatment of hepatocellular carcinoma;Cancer Nanotechnology;2024-02-22

3. A Strategy based on Bioinformatics and Machine Learning Algorithms Reveals Potential Mechanisms of Shelian Capsule against Hepatocellular Carcinoma;Current Pharmaceutical Design;2024-02

4. Sorafenib Resistance Contributed by IL7 and MAL2 in Hepatocellular Carcinoma Can Be Overcome by Autophagy-Inducing Stapled Peptides;Cancers;2023-11-03

5. Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies;Biomedicine & Pharmacotherapy;2023-11